Markets:

Overview

News

Currencies

International

Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

9.370 -0.490 (-4.97%)

Streaming Delayed Price Updated: 1:37 PM EDT, Jul 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >

Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate ↗

November 01, 2023

Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 01, 2023

Via Benzinga

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

November 01, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

September 26, 2023

From Silence Therapeutics plc

Via Business Wire

Where Silence Therapeutics Stands With Analysts ↗

August 17, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Silence Therapeutics ↗

June 26, 2023

Via Benzinga

Silence Therapeutics to Participate in September Investor Conferences

September 06, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports Second Quarter 2023 Results

August 16, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

July 11, 2023

From Silence Therapeutics plc

Via Business Wire

The Latest Analyst Ratings for Silence Therapeutics ↗

May 11, 2023

Via Benzinga

Earnings Scheduled For August 10, 2023 ↗

August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

Via Benzinga

Silence Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports First Quarter 2023 Results

May 16, 2023

From Silence Therapeutics plc

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023 ↗

May 08, 2023

Via Benzinga

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

May 04, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

May 01, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

April 25, 2023

From Silence Therapeutics plc

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

April 25, 2023

Tuesday's session saw 286 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

April 24, 2023

On Monday, 147 stocks made new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 17, 2023

Via Benzinga

Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera

April 04, 2023

From Silence Therapeutics plc

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

April 21, 2023

During Friday's session, 149 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 29, 2023

On Wednesday, 81 companies hit new 52-week lows.

Via Benzinga

Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

March 29, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

March 28, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Buyback siRNA Complement Assets

March 28, 2023

From Silence Therapeutics plc

Via Business Wire

Earnings Scheduled For March 15, 2023 ↗

March 15, 2023

Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 15, 2023

Via Benzinga

Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

March 15, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

March 02, 2023

From Silence Therapeutics plc

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

All News about Silence Therapeutics Plc - American Depository Share

Starting at /week.